• OncoProteomics Laboratory, VUmc

    Welcome to the website of the OncoProteomics Laboratory, a proteomics center with a focus on cancer proteomics and (inter)national collaboration.

  • OncoProteomics Laboratory, VUmc

    The protein wet lab where samples are prepared with dedicated benches for cell/ tissue lysis, protein electrophoresis, phosphopeptide capture and keratin-free enzymatic digestions.

  • OncoProteomics Laboratory, VUmc

    The protein wet lab where samples are prepared with dedicated benches for cell/ tissue lysis, protein electrophoresis, phosphopeptide capture and keratin-free enzymatic digestions.

  • OncoProteomics Laboratory, VUmc

    The MS lab with mass spectrometry platforms for high resolution and high-throughput proteomics analyses.

MISSION

The mission of the OPL is to develop/implement and apply innovative proteomics and data analysis strategies to improve (early) diagnostics and treatment of disease, most notably cancer.

Read more...

Comprehensive proteome analysis by MS offers a unique means to measure the biochemical impact of cancer-related genomic abnormalities, and thereby can bridge the gap between cancer genome information and observed cancer phenotype.
To this end, the activities of OPL are focused on 1) identifying protein markers for non-invasive (early) detection of cancer and for monitoring disease; 2) identifying new predictive markers/targets for targeted therapy of cancer and for tailored therapy for individual patients; and 3) developing/implementing innovative proteomics and data analysis strategies to enable the above.

ORIGINS and EMBEDDING

The OncoProteomics Laboratory (OPL) was founded in 2006 with a start-up grant of the Cancer Center Amsterdam and is embedded in the Department of Medical Oncology of the VU University Medical Center.

Read more...

OPL functions also since 2006 as a CCA enabling technology center and core facility for (cancer) proteomics, usually within the framework of collaborative projects.

In addition, OPL also supports other disease proteomics, ie., neuroproteomics (focus on CSF) with researchers of the VUmc, AMC and EMC, as well as cardio proteomics with VUmc and AMC and microbial proteomics with the VUmc and VU.

Altogether, OPL currently performs MS-based proteomics in >50 core and collaborative projects (research hotel function) with 16 different local departments, 9 national institutes, and 9 international institutes, which has resulted in over 100 peer-reviewed publications to date. See appendix 2 of the OPL progress report 2015-2017 for OPL facts.

In the past 11 years, the OPL has gained a national and international reputation in the area of clinical proteomics and cancer proteomics.

OPL RESEARCH

Most cellular functions are executed by proteins. Therefore, large-scale protein analysis through proteomics can provide an unprecedented and comprehensive source of information that uncovers the state and activity of cancer cells

Read more...

The OPL performs translational and clinical proteomics research in many collaborative projects with researchers from the CCA, VUmc, and other national institutes (NKI, AMC, UMCU, Prinses Maxima, RUMC, Erasmus MC and MUMC).

OPL’s infrastructure and (label-free) research strategies are state-of-the-art. The laboratory’s embedding in the VUmc Department of Medical Oncology and the CCA institute (with exquisitely short lines to clinical samples and expertise), provides a unique setting, enabling a research path for identification and validation of biomarkers and therapeutic targets.

This innovative, translational oncoproteomics approach has received national and international recognition as evidenced by awarded funding, the number of scientific publications (> 100 since foundation of OPL in 2006), and a large number of invited lectures at scientific meetings with a focus on proteomics and/or cancer research.

> 100
JOURNAL ARTICLES
> €12 Millon
External Grants
> 50
Core and collaborative research projects

Latest News

With our collaborator Jacco van Rheenen we performed a study entitled “ TUMOR CELLS PHENOCOPY MIGRATORY BEHAVIOR IN VIVO VIA EXCHANGE OF EXTRACELLULAR VESICLES”, that ...
March 15, a special day with the lecture and meet-the-expert session with Prof.dr. Akilesh Pandey (Hopkins University, USA) and the thesis defense of Dr. Mariette ...
Chemical proteomics shows targeted kinase inhibitors do not exist. Read more in his latest Science 2017 paper.